Vascular endothelial growth factor (VEGF) was identified by the ChIP-on-ChIP to be a direct GATA1 target is indicative of poorer prognosis [38] and is also a potential therapeutic target in AML [39]. Here, GATA1 is linked to acute myeloid leukemia.